Fulvestrant
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Fulvestrant: Original Indication Not on File — Predicted for HIV Infectious Disease
One-Sentence Summary
The evidence pack does not document Fulvestrant’s original approved indication or India market license data (0 registrations, not marketed). The TxGNN model predicts it may be effective for HIV Infectious Disease, but this direction is currently supported by 0 clinical trials and only 1 loosely related publication (which concerns HTLV-1, not HIV itself).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this evidence pack (no India-approved license record; original_indications empty) |
| Predicted New Indication | HIV Infectious Disease |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L5 |
| India Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for Fulvestrant is flagged as a data gap in this evidence pack (DG002). Based on evidence embedded elsewhere in the pack (clinical trial titles/summaries under the “multiple endocrine neoplasia” candidate), Fulvestrant is identifiable as a selective estrogen receptor degrader (SERD) used across dozens of hormone receptor-positive (HR+), HER2-negative metastatic breast cancer trials — but no original-indication or India licensing data is present here to confirm this formally for this candidate record.
For the top-ranked prediction, HIV Infectious Disease, the model’s own supporting rationale states there is no direct mechanistic link. The single literature hit is a cross-omics cohort analysis of HTLV-1-associated myelopathy (HAM) — a different retrovirus and disease from HIV — that only touches HIV tangentially as a comparator within a broader neuroinflammatory/viral-immunology framework. It is not a study of fulvestrant, estrogen-receptor biology, or antiretroviral activity.
Given the absence of any mechanistic, preclinical, or clinical connection between an anti-estrogen SERD and HIV pathophysiology, this prediction should be treated as a pure knowledge-graph signal (high TxGNN score, rank 2154) rather than a biologically grounded hypothesis at this stage.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 40343334 | 2025 | Cross-omics Cohort Analysis (Tier 3; HTLV-1, not HIV) | Research square (preprint) | Multi-cohort (epi)genomic analysis of HTLV-1-associated myelopathy (HAM), a neuroinflammatory disease; current HAM treatment is symptomatic and borrows strategies from HIV-1/MS therapy — HIV is referenced only as a comparator, not as the study subject, and fulvestrant is not mentioned. |
India Market Information
Fulvestrant is currently not marketed in India — no licenses are on file (total_licenses: 0, market_status: Not marketed).
Safety Considerations
Drug Interactions: A DDI query returned 92 total interactions on record (source: DDInter), though all listed interaction levels are classified as “Unknown” severity. Representative interacting drugs include:
| Interacting Drug | Level | Source |
|---|---|---|
| Pantoprazole | Unknown | ddinter |
| Morphine | Unknown | ddinter |
| Metformin | Unknown | ddinter |
| Omeprazole | Unknown | ddinter |
| Lansoprazole | Unknown | ddinter |
| Prednisone | Unknown | ddinter |
| Simvastatin | Unknown | ddinter |
| Potassium chloride | Unknown | ddinter |
| Ranitidine | Unknown | ddinter |
| Ondansetron | Unknown | ddinter |
| Metronidazole | Unknown | ddinter |
| Famotidine | Unknown | ddinter |
| Acetylsalicylic acid | Unknown | ddinter |
| Palonosetron | Unknown | ddinter |
| Bupropion | Unknown | ddinter |
| Calcium chloride | Unknown | ddinter |
| Metoclopramide | Unknown | ddinter |
| Dexamethasone | Unknown | ddinter |
| Promethazine | Unknown | ddinter |
| Warfarin | Unknown | ddinter |
Key warnings and contraindications are not available in this evidence pack (flagged as a data gap, DG001 — blocking for safety pre-screening). Please refer to the package insert for that information once obtained.
Conclusion and Next Steps
Decision: Hold
Rationale: The HIV infectious disease prediction has no supporting clinical trials, no mechanistically relevant literature, and the one available publication concerns a different disease (HTLV-1, not HIV). Evidence level is L5 (model prediction only), and both the drug’s original indication/MOA and its India regulatory status are undocumented data gaps — the candidate does not clear even an initial safety screen (DG001 is explicitly blocking).
To proceed, the following is needed:
- Fulvestrant’s package insert / TFDA-CDSCO label data (key warnings, contraindications) — currently blocking (DG001)
- Verified mechanism of action documentation (DG002)
- Confirmation of Fulvestrant’s actual original indication and any India licensing status
- Any preclinical or in vitro data specifically linking estrogen receptor modulation to HIV viral replication or immune response, if such a hypothesis is to be pursued further
- DDI severity grading (current list shows “Unknown” levels for all 92 interactions, which is not actionable for risk assessment)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.